sellWeak cluster of 4
Martin Auster sold $7,592 of VTYX
CHIEF FINANCIAL OFFICER at Ventyx Biosciences, Inc.. 1,405 shares at an average of $5.40, traded Apr 2, 2024, filed Apr 3, 2024.
Warning score
37Value
$7,592
1,405 shares
Holdings after
24,303
-5% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- 0Trade size$8k at market
- 0Share of holdings soldSold 5.5% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-24-010177, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 2, 2024 | SOpen-market sale Common Stock | -1,405 | $5.40 | $7,592 | 24,303 | Apr 3, 2024 |
Related signals
Other insiders at Ventyx Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | Ventyx Biosciences, Inc. | Raju Mohan CEO AND PRESIDENT | $365k 47,345 shares | -2% | |
| 18Weak | Ventyx Biosciences, Inc. | John Nuss CHIEF SCIENTIFIC OFFICER | $98k 12,675 shares | -3% | |
| 15Weak | VTYXsell Ventyx Biosciences, Inc. | John Nuss CHIEF SCIENTIFIC OFFICER | $2,019 1,887 shares | -0% | |
| 22Weak | VTYXsell Ventyx Biosciences, Inc. | John Nuss CHIEF SCIENTIFIC OFFICER | $50k 21,119 shares | -4% | |
| 37Weak | VTYXbuy Ventyx Biosciences, Inc. | Sheila Gujrathi director | $301k 130,000 shares | - | |
| 5Weak | VTYXsell Ventyx Biosciences, Inc. | John Nuss CHIEF SCIENTIFIC OFFICER | $30k 13,161 shares | -3% | |
| 55Moderate | VTYXbuy Ventyx Biosciences, Inc. | Raju Mohan CEO AND PRESIDENT | $960k 500,000 shares | +30% | |
| 30Weak | Ventyx Biosciences, Inc. | Christopher W Krueger CHIEF BUSINESS OFFICER | $8,921 1,651 shares | -1% | |
| 40Moderate | Ventyx Biosciences, Inc. | Raju Mohan CEO AND PRESIDENT | $23k 4,312 shares | -0% | |
| 30Weak | Ventyx Biosciences, Inc. | John Nuss CHIEF SCIENTIFIC OFFICER | $8,921 1,651 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.